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Lytic bone disease is a frequent complication of multiple
myeloma (MM). Lytic lesions rarely heal and X-rays are of
limited value in monitoring bone destruction during anti-
myeloma or anti-resorptive treatment. Biochemical markers of
bone resorption (amino- and carboxy-terminal cross-linking
telopeptide of type I collagen (NTX and CTX, respectively) or
CTX generated by matrix metalloproteinases (ICTP)) and bone
formation provide information on bone dynamics and reflect
disease activity in bone. These markers have been investigated
as tools for evaluating the extent of bone disease, risk of
skeletal morbidity and response to anti-resorptive treatment in
MM. Urinary NTX, serum CTX and serum ICTP are elevated in
myeloma patients with osteolytic lesions and correlate with
advanced disease stage. Furthermore, urinary NTX and serum
ICTP correlate with risk for skeletal complications, disease
progression and overall survival. Bone markers have also been
used for the early diagnosis of bone lesions. This International
Myeloma Working Group report summarizes the existing data
for the role of bone markers in assessing the extent of MM bone
disease and in monitoring bone turnover during anti-myeloma
therapies and provides information on novel markers that may
be of particular interest in the near future.
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Introduction
Multiple myeloma (MM) is characterized by the presence of
osteolytic bone lesions that result in skeletal-related events
(SREs), such as pathologic fractures, need for radiation or surgery
to bone, spinal cord compression and hypercalcemia. In the
absence of effective bisphosphonate therapy, more than 50% of
patients with Durie–Salmon stage III MM will experience at least
one SRE over 2 years.1 The development of lytic bone lesions is
not only related to increased osseous breakdown but also to
uncoupling of the bone remodeling process, in which
osteoclast-mediated bone resorption is normally tightly coupled
both temporally and spatially with osteoblast-mediated bone
formation.2–4 Lytic lesions rarely heal even in patients at
complete remission.4 Further, owing to the marked decrease
in osteoblast activity, bone scans are often negative in myeloma
patients with extensive lytic lesions and offer very little in the
follow-up of bone disease in these patients.5,6 Finally, sequential
measurement of bone mineral density using Dual-energy X-ray
Absorptiometry scans produce heterogeneous local bone
mineral density changes; as such the routine use of sequential
Dual-energy X-ray Absorptiometry scans is not recommended to
assess bone disease in MM.6,7
Although osteolytic lesions are usually assessed by plain
radiographs, conventional radiography cannot provide informa-
tion about ongoing bone remodeling.6 Accordingly, biochem-
ical markers of bone metabolism have been used in MM to
assess the rate of bone turnover (defined as the prevalent rates of
both bone formation and bone resorption) and to improve
monitoring of bone destruction in MM. Moreover, bone turnover
markers have been used to follow myeloma bone disease during
specific therapies.8–10 However, at present there is no consensus
for the use of bone turnover markers in MM. This report of the
International Myeloma Working Group summarizes the existing
data for the role of markers of bone remodeling in assessing the
extent of myeloma bone disease and in monitoring bone
turnover during anti-myeloma treatment. It also proposes
markers that can be used in clinical practice, and presents
novel markers that may be of particular interest in the future.
Markers of bone remodeling
Throughout life, bone undergoes continuous remodeling with
removal of old bone by osteoclasts and replacement with new
bone by osteoblasts; a process that is balanced under normal
conditions.11 However, in MM, there is increased activation of
osteoclasts and suppression of osteoblast function.2–4 Over the
past two decades, the isolation and characterization of cellular
and extracellular components of the skeletal matrix have
resulted in the development of biochemical markers that reflect
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either bone formation or bone resorption.12–15 Markers of bone
resorption and formation are depicted in Tables 1 and 2.
Measurement of bone turnover markers is noninvasive, compara-
tively inexpensive and when applied and interpreted correctly,
can be of significant help in the assessment of bone disorders.
However, factors that affect bone turnover marker levels,
including circadian rhythm, diet, age, gender, renal function
and drugs, should be clearly defined and appropriately adjusted
for whenever possible. It is also important to recognize that these
biochemical measurements reflect whole-body bone turnover
and give little information about the function of local changes in
skeletal homeostasis. All these issues are discussed below.
Biochemistry of bone markers
Bone resorption markers
Hydroxyproline (Hyp) and hydroxylysine (Hyl). Hyp is
formed in the cell from the post-translational hydroxylation of
proline and is the predominant amino acid within all collagens.
Hyl is another structural amino acid of collagenous proteins.11
However, both Hyp and Hyl are also contained in certain serum
proteins, such as the C1q component of complement. This
disadvantage, in combination with the effect of age and
circadian rhythm (both Hyp and Hyl have their peak excretion
after midnight) on their circulating levels, makes both Hyp and
Hyl less specific indices of bone resorption. As such, both have
been largely replaced by newer markers.17–19
Pyridinoline (PYD) and deoxypyridinoline (DPD) cross-
links of type I collagen. PYD and DPD are formed by the
enzymatic action of lysyl oxidase on lysine and Hyl. PYD and
DPD act as mature cross-links in type I collagen of all major
connective tissues (Figure 1).20 The products of bone collagen
degradation by osteoclasts include amino- and carboxy-terminal
peptide fragments (NTX and CTX, respectively) of various sizes
that remain attached to helical portions of nearby collagen
molecules by a pyridinium cross-link. These molecules are
released into the circulation. Further degradation occurs in the
liver and kidney, where the fragments are finally degraded to
their constituent amino acids and the pyridiniums, PYD and
Table 1 Markers of bone resorption
Marker Abbreviationa Tissue of origin Analytical method Analytical specimen
Hydroxyproline Hyp All tissues and all genetic
types of collagen
Colorimetric, assay,
HPLC
Urine
Hydroxylysine Hyl All tissues and all genetic
types of collagen
Reversed-phase HPLC Urine
Galactosyl-
hydroxylysine
Gal-Hyl Both Gal-Hyl and Glc-Gal-
Hyl appears to be specific
for bone collagen
degradation
Reversed-phase HPLC Urine
Glucosyl- galactosyl-
hydroxylysine
Glc-Gal-Hyl Bone, cartilage, tendon,
blood vessels
Reversed-phase HPLC Urine
Pyridinoline PYD Bone, dentin HPLC, ELISA Urine
Deoxypyridinoline DPD All tissues containing type-I
collagen
RIA Urine (free DPD can be
also measured in serum
or plasma)
N-terminal cross-linking
telopeptide of type-I
collagen
NTX All tissues containing type-I
collagen
ELISA, RIA Urine, serum
C-terminal cross-linking
telopeptide of type-I
collagen
CTX All tissues containing type-I
collagen
ELISA, RIA Urine, serum (b-form
only)
C-terminal cross-linking
telopeptide of type-I
collagen generated by
MMPs
CTX-MMP or
ICTP
All tissues containing type-I
collagen
RIA Serum
Tartrate-resistant acid
phosphatase isoform 5b
TRACP-5b Bone (osteoclasts) Colorimetric RIA, ELISA Serum, plasma
Bone sialoprotein BSP Bone, dentin, hypertrophic
cartilage, cancer cells
RIA, ELISA Serum
Abbreviations: ELISA, enzyme-linked immunosorbent assay; HPLC, high-performance liquid chromatography; MMP, matrix metalloproteinase;
RIA, radioimmunoassay.
aAccording to the bone marker nomenclature by the Committee of Scientific Advisors of the International Osteoporosis Foundation.16
Table 2 Markers of bone formation
Marker Abbreviationa Tissue of origin Analytical method Analytical specimen
Osteocalcin (or bone gla-protein) OC Bone, platelets RIA, ELISA, IRMA Serum
Bone-specific alkaline phosphatase Bone ALP Bone ELISA, IRMA, colorimetric assay Serum
Procollagen type-I N-propeptide PINP Bone, soft tissue, skin RIA, ELISA Serum
Procollagen type I C-propeptide PICP Bone, soft tissue, skin RIA, ELISA Serum
Abbreviations: ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay; IRMA, immunoradiometric assay.
aAccording to the bone marker nomenclature by the Committee of Scientific Advisors of the International Osteoporosis Foundation.16
Bone markers in multiple myeloma
E Terpos et al
1701
Leukemia
DPD. The measurement of urinary DPD and PYD is not
influenced by the degradation of newly synthesized collagen
fibrils or by dietary collagen intake. Further, unlike Hyp, the
PYD amino acids are fully excreted with no known pathway of
metabolic degradation.21
Amino- and Carboxy-terminal cross-linking telopeptide
of type I collagen. During bone collagen degradation by
osteoclasts, NTX and CTX fragments are released into the
circulation.21 These fragments represent a spectrum of proteins
of different molecular weights. The proteolytic activities of
cathepsin K and matrix metalloproteinases result in the
production of a variety of degradation peptides with different
antigenic properties.22 The majority of these peptides is
relatively small and is freely filtered by the glomerulus into the
urine. NTX fragments are considered specific for bone tissue
breakdown, as other tissues that contain type I collagen, for
example, skin, do not undergo osteoclast-mediated metabolism.
Thus, different type I collagen fragments are formed during the
breakdown of non-skeletal tissues.15
An enzyme-linked immunosorbent assay method has been
developed to recognize a discrete pool of NTX isolated from
urine, namely the a2-chain N-telopeptide fragment.23 Although
this fragment contains the pyridinium cross-links, the assay does
not recognize the PYD and DPD per se. This confers bone
specificity, as the PYD cross-link in bone primarily involves the
a2-chain, whereas in other tissues the a1-chain predominates.23
NTX contains the cross-linked a2 N-telopeptide sequence
QYDGKGVG, which is a product of osteoclastic proteolysis,
in which lysine (K) is embodied in a trivalent cross-linkage.
Collagen must be degraded to small cross-linked peptides that
contain this exact sequence before the antibody will recognize
the NTX antigen. This ensures that the NTX peptide is a direct
product of osteoclastic proteolysis that does not require further
metabolism in the liver or kidney for generation, and is rapidly
cleared by the kidney.24 Urinary NTX results are expressed
relative to creatinine as nM of bone collagen equivalent per mM
of creatinine.
Other assays have also been developed for the measurement
of epitopes associated with CTX (a-CTX, b-CTX and CTX
generated by matrix metalloproteinases (ICTP)) in both serum
and urine.25,26 These include a radioimmunoassay that detects
ICTP by rabbit polyclonal antibodies directed against a large
antigen (10 000 Da) with a preserved trivalent cross-linked
structure.27 This antigen is liberated when type I collagen is
degraded by matrix metalloproteinases.22,28 In contrast to the
approach used in the ICTP assay, the CTX-I (b-CTX) antigen is
liberated when type I collagen is degraded by cathepsin K, but
not by matrix metalloproteinases.26 The recognized antigen
must be cross-linked, but can be imbedded into fragments of
the C-terminal telopeptide of variable size (1000–10 000 Da).
As half of the recognized antigens in normal sera are smaller
than 3000 Da, it is smaller than the ICTP antigen.
Owing to specificity for type I collagen and their unique
characteristics, the bone resorption markers NTX, ICTP and CTX
have almost completely replaced the use of older resorption
indices in the diagnostic assessment of bone disease.
Tartrate-resistant acid phosphatase isoform 5b (TRACP-
5b). Two forms of TRACP circulate in human
serum, macrophage-derived TRACP-5a and osteoclast-derived
TRACP-5b.29–31 In human serum, TRACP-5b circulates in a
large complex that contains a2-microglobulin and calcium.
32
Osteoclasts secrete TRACP-5b into the circulation as a cata-
lytically active enzyme that is inactivated and degraded to
fragments in the circulation. Thus, TRACP-5b molecules mea-
sured in serum are freshly liberated from osteoclasts, providing a
resorptive index that is useful as a surrogate marker for total
activated osteoclast numbers.29
Bone formation markers
Bone-specific alkaline phosphatase (ALP). ALP is a
ubiquitously expressed, cell membrane-associated enzyme.33
Liver and bone (bALP) isoforms account for almost 95% of the
total ALP activity in the serum. bALP is produced by osteoblasts
and has been demonstrated in matrix vesicles deposited as
‘buds’ derived from the cell membrane. These deposits have an
important role in bone formation.15 bALP is produced in
extremely high amounts during the bone formation phase of
bone turnover, and is, therefore, an excellent indicator of total
bone formation activity.33
Osteocalcin (OC). OC is one of the most abundant non-
collagenous proteins within bone. It is produced by osteoblasts,
odontoblasts and hypertrophic chondrocytes. Most of the
circulating OC is a product of osteoblast activity. OC is
incorporated into bone matrix, where it serves to bind calcium;
as such, OC is considered a marker of bone formation. OC is a
small protein of 49 amino acids. In serum, OC is degraded so
that both the intact peptide and fragments coexist in the
circulation.34–38 Thus, assays that evaluate both intact OC and
OC fragments are more accurate for the measurement of serum
OC. Serum levels of OC are significantly influenced by gender,
age and renal function.36
Type I procollagen propeptides. Collagen type I is a
300-kDa protein that comprises 90% of the organic bone matrix.
It is synthesized by osteoblasts in the form of procollagen.
Extracellular processing of procollagen before collagen fiber
assembly includes cleavage of the amino- and carboxy-terminal
extension propeptides (termed procollagen type I N-propeptide
(PINP) and C-propeptide (PICP)).39 Circulating PINP is cleared
by the scavenger endothelial system in the liver, whereas PICP is
removed from the circulation by the mannose receptors on liver
endothelial cells.40 Because PINP and PICP peptides are
generated in a stoichiometric 1:1 ratio with newly formed
collagen molecules, their serum levels are considered an index
of collagen synthesis and thus of bone formation.41 Most studies
suggest that the PINP has a greater diagnostic validity than PICP
in metastatic bone disease.42
Figure 1 Fibrils of collagen showing the N- and C-terminal ends
bonding to helical areas of adjacent fibrils by pyridinoline and
deoxypyridinoline crosslinks.
Bone markers in multiple myeloma
E Terpos et al
1702
Leukemia
Markers of bone remodeling in myeloma bone disease
Bone turnover markers and extent of myeloma
bone disease
Markers of both resorption and formation have been used in
attempts to better evaluate the extent of bone disease in MM.
Table 3 summarizes the results of the most important studies to
date regarding the levels of bone markers in MM patients.43–60
As has been shown in multiple studies, urine levels of PYD,
DPD and NTX and serum levels of CTX, ICTP and TRACP-5b
were elevated in MM patients compared with healthy controls,
and correlated with the extent of osteolytic disease.46,48,51–56,58–60
Urinary NTX levels were increased even in myeloma patients
who had reached a clinical plateau phase of their disease,61
whereas PYD, DPD and NTX were also elevated in myeloma
patients before autologous transplantation.62,63
A histomorphometric study in bone marrow biopsies of
myeloma patients showed that urinary NTX correlated most
positively with dynamic histomorphometric indices of bone
resorption, followed by serum ICTP and urine DPD; urine PYD
did not correlate with the histomorphometric findings.64 More-
over, comparison between these four markers (PYD, DPD, NTX
and ICTP) revealed that serum ICTP and urinary NTX
better reflected the extent of myeloma bone disease and could
better predict early progression of the bone disease after
conventional chemotherapy (CC).6,54 However, serum ICTP
remained more sensitive than the urinary assays when
patients with impaired renal function were excluded from that
analysis.54
Jakob et al. demonstrated that serum ICTP was elevated in
MM patients who did not have detectable osteolytic lesions by
plain radiograph, but had abnormal bone magnetic resonance
imaging scans.65 Urinary NTX also correlated with the overall
score of skeletal involvement as measured by Tc-99m-MIBI
scintigraphy and bone marrow infiltration by plasma cells.66
Coleman et al. showed in 210 MM patients that high or
intermediate urinary NTX correlated with an increased risk for
SRE development compared with low NTX values (risk ratio (RR)
2.25, P¼ 0.032 and RR 1.75, P¼ 0.016, respectively).57 High
NTX values also correlated with a three-fold increased risk for
developing a first SRE (Figure 2), whereas there was also a trend
toward increased risk for progression of osteolytic lesions in the
high NTX group (P¼ 0.08).57 A recent study by Terpos et al. in
282 myeloma patients who participated in a randomized phase
III study comparing zoledronic acid and pamidronate showed
that high urinary NTX was independently associated with
elevated risk for the development of first SRE (68% increase in
risk for SRE development per 100-unit increase of NTX;
P¼ 0.005).67 In summary, these results suggest that serum ICTP
and urinary NTX strongly correlate with the extent of MM bone
disease, the risk for the development of SREs, and possibly with
risk for MM progression.
Markers of bone formation have been evaluated in several
studies, but the results have been more variable than those
found with bone resorption markers.43–46,48–51,53,55,56 In some
studies, bALP and OC were elevated in myeloma patients
compared with controls, whereas in others they were either
reduced or within normal limits. In a study by Fonseca et al.,
which included a large number of myeloma patients (n¼ 313),
serum bALP correlated with bone pain, lesions and fractures,
whereas OC levels were lower in myeloma patients than in
controls but did not correlate with the extent of bone disease.48
Furthermore, Coleman et al. showed that myeloma patients
with high bALP levels are at increased risk for developing a SRE
(RR 3.29; Po0.001) and for disease progression (RR 2.42;
Po0.001).57 Terpos et al. showed that OC levels were reduced
in myeloma patients and correlated with the extent of bone
disease, whereas bALP levels were not.55 Why differences
between the studies exist is not clear, but may reflect different
study populations and/or different phases of bone turnover in
each population. PICP values do not seem to reflect the extent of
myeloma bone disease.43–46,48 As shown in Table 3, although
markers of bone formation may be of some value in myeloma,
they do not appear to reflect the extent of myeloma bone
destruction. Thus at present, their clinical utility is doubtful.
Correlations of bone turnover markers with myeloma
activity and survival
In several studies, biochemical markers of bone resorption
strongly correlated with stage of MM. Serum ICTP and urinary
NTX were higher in myeloma stage II/III than in stage I
disease.44,48,53 High DPD urinary levels also correlated with
advanced myeloma stage.51,52 In 121 newly diagnosed myelo-
ma patients, NTX and TRACP-5b, but not OC or bALP, strongly
correlated with disease stage.55 Two additional studies also
failed to show a correlation between OC and bALP with
myeloma stage.48,51
Markers of bone remodeling have also correlated with well-
characterized markers of disease activity, such as b2-micro-
globulin and interleukin-648,51,55,64 and also with overall
survival (OS).44,46,48,52,68,69 Fonseca et al. showed that the
median survival was 4.1 and 3.5 years for patients who received
CC and had low or high ICTP levels, respectively (P¼ 0.02).48
Jakob et al. also reported that ICTP is a prognostic factor for OS
in MM patients treated with CC (Po0.03), whereas urinary NTX
was only of borderline prognostic value (P¼ 0.05).52 The same
group showed in 100 patients with newly diagnosed sympto-
matic MM that disease stage, according to International Staging
System, del(13q14), high dose therapy and ICTP independently
predicted for OS, with ICTP having the most powerful
prognostic value (hazard ratio: nine-fold increase; Po0.001).
Incorporation of ICTP in the International Staging System
separated four risk groups with a 5-year OS rate of 95, 65, 46
and 22%, respectively.60
Abildgaard et al., using sequential measurements of both ICTP
and NTX showed that high levels of ICTP and NTX correlated
with an increased risk for early progression of bone lesions
during CC, suggesting that their measurements are clinically
useful for identifying patients with increased risk of early disease
progression.7 In a recent study, Terpos et al. analyzed the effect
of urinary NTX on survival in 210 patients participating in a
randomized study comparing treatment with either zoledronic
acid or pamidronate. Increased baseline levels of urinary NTX
(X50 nM bone collagen equivalent per mM creatinine) corre-
lated with an 88% increased risk of death and a 67% increased
risk of first SRE (Figure 3).70 The update of this study in 282
patients confirmed that high urinary NTX independently
predicted for poor survival (RR¼ 1.60; P¼ 0.017).67 These data
suggest that the bone resorption markers serum ICTP and urinary
NTX have prognostic significance for disease progression and
survival in MM under CC, and that their routine measurement in
future clinical trials may be of prognostic value in the current era
of novel anti-MM agents. In contrast, measurement of bone
formation markers seem to be of limited prognostic value.71
Bone markers during anti-resorptive therapy
Biochemical markers of bone turnover have been used in MM
both to monitor bisphosphonate treatment, and to determine
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Table 3 Markers of bone remodeling in myeloma patients and correlations with clinical data
Authors (year) No. of
patients
Parameter
studied
Comparison with controls
(symbol refers
to MM patients)
Correlation with
extent of bone
disease
Correlation with
survival (in multivariate
models)
Nawawi et al., 199643 17 DPD
TRACP
OC
bALP
PICP
m
NS
NS
NS
NS
NA NA
Abildgaard et al., 199744 109 ICTP
OC
bALP
PICP
PIIINP
m
NS
m
NS
m
NA Yes
Yes
No
No
No
Withold et al., 199845 15 DPD, PYD
bALP, PICP
m
k
NA NA
Carlson et al., 199946 73 DPD
ICTP
OC
PICP
m
m
NS
NS
Yes
Yes
No
No
No
Yes
No
No
Woitge et al., 199947 18 PYD
DPD
NTX
CTX
BSP
m
m
m
m
m
NA NA
Fonseca et al., 200048 313 ICTP
TRACP
OC
bALP
PICP
m
m
k
NS
NS
Yes
No
No
Yes
No
Yes
No
No
No
No
Terpos et al., 200049 62 NTX m NA NA
OC k
bALP k
Woitge et al., 200150 43 OC NS NA NA
bALP k
Corso et al., 200151 52 DPD
OC
bALP
m
k
NS
Yes
No
No
NA
Jakob et al., 200252a 57 DPD m Yes No
NTX NS No P¼ 0.05
ICTP m Yes Yes
Alexandrakis et al., 200253 38 PYD m Yes NA
DPD m Yes
NTX m Yes
OC m No
bALP NS No
Abildgaard et al., 200354 34 PYD m Yes NA
DPD m Yes
ICTP m Yes
NTX m Yes
Terpos et al., 200355,56 121 NTX m Yes No
TRACP-5b m Yes No
OC k Yes No
bALP k No No
sRANKL/OPG m Yes Yes
Coleman et al., 200557 318 NTX m Yesb Yes
Kuliszkiewicz-Janus et al., 200558 75 ICTP
OC
m
NS
Yes
No
NA
Dizdar et al., 200759 25 CTX m Yes NA
DPD m Yes
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those subjects who would benefit most from bisphosphonate
therapy.45,49,57,61,71–75 Clodronate administration resulted in a
significant reduction of ICTP and PINP in 244 MM patients
compared with controls.71 Terpos et al. showed that the addition
of pamidronate to CC significantly reduced urinary NTX and
disease-related pain compared with CC alone,49 and that
pamidronate in combination with interferon-a induced bone
formation in MM patients at plateau phase.61 Ibandronate at a
dose of 2 mg showed a substantial reduction of CTX and OC in
only one-third of MM patients,74 whereas in a randomized
study, monthly pamidronate (90 mg, IV) produced a greater
reduction of NTX and TRACP-5b compared with monthly
ibandronate (4 mg, IV).56,75 In a large, randomized study
comparing 4 mg zoledronic acid with 90 mg pamidronate, given
IV every 3–4 weeks in patients with bone metastases from breast
cancer or with MM osteolytic disease, urinary NTX was strongly
suppressed (up to 64% below baseline in both treatment groups)
for the duration of the study.73 Bone marker data from this and
other bisphosphonate studies clearly demonstrate that there is a
subset of myeloma patients who do not respond to, or who
Table 3 (Continued )
Authors (year) No. of
patients
Parameter
studied
Comparison with controls
(symbol refers
to MM patients)
Correlation with
extent of bone
disease
Correlation with
survival (in multivariate
models)
Jakob et al., 200860 100 ICTP ma Yes Yes
Terpos et al., 201067 282 NTX NA NA Yesc
DPD NA NA No
Abbreviations: bALP, bone-specific alkaline phosphatase; BSP, bone sialoprotein; CTX, carboxy-terminal cross-linking telopeptide of type I
collagen; DPD, deoxypyridinoline; ICTP, carboxy-terminal cross-linking telopeptide of type I collagen generated by matrix metalloproteinases;
NA, not assessed; NS, non significant; NTX, amino-terminal cross-linking telopeptide of type I collagen; OC, osteocalcin; OPG, osteoprotegerin;
PICP, procollagen type I C-propeptide; PIIINP, N-terminal propeptide of procollagen type III; PYD, pyridinoline; sRANKL, soluble receptor activator
of nuclear factor-kB ligand; TRACP-5b, tartrate-resistant acid phosphatase isoform 5b.
aMM compared with MGUS patients.
bCorrelation with SREs.
cIn this study high NTX also independently predicted for high risk for development of first SRE.
Figure 2 Relative risk for experiencing any skeletal-related event (SRE) and a first SRE for multiple myeloma patients with high levels of
N-telopeptide of type I collagen (NTX;X100 nM bone collagen equivalent (BCE)/mM creatinine) or moderate NTX (50–99 nM BCE/mM creatinine)
versus patients with low NTX (o50 nM BCE/mM creatinine) treated with zoledronic acid. Length of horizontal lines represents 95% confidence
intervals.57,77
Figure 3 Kaplan–Meier Curves for (a) survival and (b) first on-study SRE by baseline NTX levels in 210 myeloma patients treated with
conventional chemotherapy and zoledronic acid.70 NTX, N-terminal cross-linking telopeptide of type l collagen; E, elevated; N, normal; RR, risk
ratio; CI, confidence interval; SRE, skeletal-related event.
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become refractory to bisphosphonate therapy.76 Patients with
persistently elevated bone marker levels are at higher risk for
SREs and disease progression compared with patients who
respond to bisphosphonate therapy and have normalized bone
resorption. Lipton et al. showed that among breast cancer or
myeloma patients (n¼ 170) who had high baseline NTX levels
(X64 nM bone collagen equivalent per mM creatinine), those
with persistently elevated NTX levels after 3 months of
zoledronic acid therapy (n¼ 26, 15%) had a significantly
increased risk of developing a first SRE (RR¼ 1.71; P¼ 0.035)
and shorter SRE-free survival (RR¼ 1.65; P¼ 0.039) compared
with subjects who normalized NTX in response to bispho-
sphonate treatment (n¼ 137, 81%).77 In this study, among
patients with high NTX at baseline, 15% treated with zoledronic
acid and 30% treated with pamidronate did not normalize NTX
levels after 3 months of bisphosphonate therapy. Although
unknown, one might speculate that patients who did not have
biochemical improvement in their NTX levels may have an
osteoclast-independent mechanism of bone resorption and
might, therefore, benefit from additional therapies.77
Denosumab is a fully human monoclonal antibody against
receptor activator of nuclear factor-kB ligand (RANKL), the most
potent osteoclast activator to-date (see below). In a recent study,
1776 adult patients with solid tumors or MM (n¼ 10% of the
total) who were naive to intravenous bisphosphonates were
randomized to receive either subcutaneous denosumab 120 mg
or intravenous zoledronic acid every 4 weeks. Denosumab
produced similar results regarding the delay in time to first on-
study SRE or subsequent SREs compared with zoledronic acid,
whereas it also rapidly and potently reduced (by more than 80%
within the first month) urinary NTX levels.78
Novel molecules related to bone remodeling and
myeloma bone disease
RANKL and Osteoprotegerin (OPG). RANKL and OPG
have crucial roles in the development of myeloma bone disease.
Although RANKL increases osteoclastogenesis and osteoclast
activity, OPG serves as a soluble inhibitor of RANKL activity.
Within the myeloma bone marrow microenvironment, the
RANKL/OPG ratio is shifted in favor of RANKL, leading to
increased osteoclastogenesis and increased bone resorption.2–4
Multiple studies have now documented that in MM, serum OPG
levels are reduced, whereas the soluble RANKL/OPG ratio is
increased.63,79–82 This altered ratio correlates with extent of
bone disease, markers of bone resorption, such as NTX and
TRACP-5b and myeloma stage.63,81 The administration of
zoledronic acid in patients with asymptomatic myeloma was
found to increase serum levels of OPG and thus reduce the
RANKL/OPG ratio, likely accounting for the effect of zoledronic
acid on osteoblast and/or bone marrow stromal cells together
with its direct effect on osteoclasts.83 The RANKL/OPG ratio has
been found to correlate with OS in MM. This result has not been
confirmed in all reported studies to date,63,69,83,84 may be due to
differences in patient populations and/or therapies administered.
Further studies are needed before measurement of serum
RANKL and OPG levels in the everyday clinical setting should
be considered.
Other potential molecules reflecting bone destruction in
MM. Bone sialoprotein is a phosphorylated 70–80 kDA
glycoprotein that accounts for 5–10% of the non-collagenous
bone matrix. Bone sialoprotein is involved in the adhesion of
bone resorbing cells to the extracellular bone matrix.82 In one
study of MM, bone sialoprotein levels were associated with
skeletal involvement and tumor cell burden.14 However, further
evaluation is needed to support its value in MM bone disease.
Dickkopf-1 (Dkk-1) protein is an inhibitor of the Wingless-
type and Int (Wnt) pathway, a pathway crucial for stimulation of
osteoblast activity. Tian et al. were the first to describe that
increased expression of Dkk-1 in plasma cells correlates with
the presence of lytic lesions both by plain radiography and
magnetic resonance imaging.85 Bone marrow plasma Dkk-1
levels were increased in MM patients, and associated with Dkk-1
concentrations in peripheral blood, levels of Dkk-1 transcripts in
myeloma cells and the presence of osteolytic lesions.86–88 Gene
expression studies in 171 newly diagnosed MM patients showed
that overexpression of Dkk-1 correlated with the degree of
osteolytic bone disease.89 Similarly, serum Dkk-1 levels were
elevated in myeloma patients with lytic bone disease compared
with those without lytic lesions by conventional radiography,
and also correlated with the number of bone lesions.87 In
contrast, patients with monoclonal gammopathy of undeter-
mined significance had lower serum levels of Dkk-1 compared
with MM subjects, with levels similar to those found in control
subjects. High values of serum Dkk-1 also correlated with
advanced ISS stage.87 It is interesting that, a recent report from
Yaccoby and colleagues demonstrated that Dkk-1-negative
myeloma cells in trephine biopsies had more aggressive features
and plasmablastic morphology, whereas Dkk-1 was rarely
expressed by plasma cells of plasma cell leukemia.90 The
current role of Dkk-1 in the clinical assessment of myeloma
bone disease, however, remains to be determined.
The effect of novel anti-myeloma agents on markers of bone
remodeling
During the last decade, immunomodulatory drugs, including
thalidomide and lenalidomide and proteasome inhibitors, such
as bortezomib, have been increasingly used for the treatment of
MM. Thalidomide, lenalidomide and bortezomib are effective
agents for the treatment of both newly-diagnosed and relapsed/
refractory MM. The role of these drugs in bone metabolism has
been evaluated in several studies.
Immunomodulatory drugs
Two clinical phase II trials have studied the effect of thalidomide
on bone metabolism of MM patients (Table 4). In the first study,
Terpos et al showed that in relapsed/refractory MM patients, the
combination of thalidomide (200 mg per day) with dexametha-
sone (TD) produced a significant reduction of serum levels of
CTX, TRACP-5b and sRANKL/OPG after 6 months of therapy.
There was a strong correlation between changes in the sRANKL/
OPG ratio and changes in TRACP-5b and CTX, suggesting that
the reduction of bone resorption by TD is at least in part due to
the reduction of RANKL. TD showed no effect on bone
formation in that study.76 In the second study, Tosi et al showed
in newly diagnosed MM patients that the combination of TD and
zoledronic acid for 4 months produced a significant reduction of
urinary NTX and serum CTX, but only in patients who
responded to therapy. This reduction was accompanied by a
reduction in bone pain in 60% of the patients, and also by a
reduction of bALP and OC levels in both responding and
refractory patients. This negative effect of TD on bone formation
may be due to the concomitant use of high-dose dexamethasone
in these patients.91
Limited data exists for the effects of lenalidomide on bone
remodeling in myeloma patients. In a small study, lenalidomide
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reduced serum RANKL and increased serum OPG levels,
leading to a reduction of the RANKL/OPG ratio.92 From the
available data, it seems that immunomodulatory drugs reduce
osteoclast function but have little or no effect on osteoblast
activity.
Bortezomib
An increasing number of studies have now reported the
beneficial effects of bortezomib on bone formation in the
clinical setting, confirming preclinical observations.93,94 As
described by Heider et al., the combination of bortezomib±
dexamethasone produced significant increases in serum bALP
and OC in both responders and non-responders.95 Giuliani et al.
found significant increases in the number of osteoblasts per mm2
of bone tissue in trephine biopsies of patients responding to
bortezomib, but not in subjects who did not respond.96 Terpos
et al. showed that, in 34 patients bortezomib monotherapy
reduced serum Dkk-1 and RANKL levels. This was asso-
ciated with a concomitant reduction in bone resorption (serum
TRACP-5b and CTX) and increase in markers of bone formation
(serum bALP and OC), changes that occurred irrespective of
response to therapy.97
However, when bortezomib was combined with other anti-
myeloma agents (VMDT regimen, combination of bortezomib,
melphalan, dexamethasone and thalidomide), the reduction of
Dkk-1, sRANKL and CTX was not accompanied by increases in
bALP and OC.83 This observation suggests that bortezomib may
lose its beneficial effect on osteoblasts when it is combined with
other anti-myeloma agents. Indeed, Heider et al. found an
attenuated increase in bALP in patients who received VD
compared with those who received bortezomib monotherapy.95
Thus, although different effective anti-myeloma regimens in
combination with bisphosphonates can reduce bone resorption
through reduction of tumor burden and inhibition of osteoclast
function,63 to-date only bortezomib has clearly shown an
anabolic bone effect in MM.
Conclusions and future directions
Biochemical markers of bone resorption faithfully reflect
changes in bone metabolism associated with the malignant
process in myeloma. Serum ICTP and urinary NTX seem to be
more accurate than other bone resorption markers in reflecting
both the severity of bone destruction and the efficacy of
response to bisphosphonate treatment. To date, data on CTX
remain sparse, but studies are ongoing. There is also a strong
correlation between serum ICTP and urinary NTX with
increased risk for progressive bone disease, development of
SREs and OS (Table 5). However, it should be kept in mind that
ICTP and CTX undergo renal elimination, a fact that will affect
the potential utility of these measurements in many patients
because of the high prevalence of renal dysfunction in MM.
Symptomatic patients who continue to have increased levels
of NTX after 3 months of anti-myeloma and anti-resorptive
therapy remain at high risk for both SREs and shortened OS;
accordingly such patients may require more aggressive therapy.
The value of bone markers in the setting of asymptomatic
myeloma has also to be evaluated as it may reveal patients at
high risk for progression (Table 5).
Table 4 Clinical studies for the effect of novel anti-myeloma agents on bone metabolism
Agent MM study
population
No. of
patients
Results Subpopulation
analysis
Thalidomide (+Dexa)
Tosi et al.91a Newly diagnosed 40 k Bone resorption markers (CTX & NTX)
k bone formation markers (bALP & OC)
In responders
In all patients
Terpos et al. 76a Refractory/relapsed 35 k Bone resorption markers (CTX & TRACP-5b)
k osteoclast stimulators (sRANKL, sRANKL/OPG ratio)
2 bone formation markers (bALP & OC)
In all patients
In all patients
In all patients
Lenalidomide
Breitkreutz et al.92 Refractory/relapsed 11 k osteoclast numbers
k osteoclast differentiation
k bone resorption
ND
Bortezomib (±Dexa)
Heider et al.95a Refractory/relapsed 58 m bone formation markers (bALP & OC) In all patients
Terpos et al.97a Refractory/relapsed 34 k bone resorption markers (CTX & TRACP-5b)
k osteoclast stimulators (sRANKL, sRANKL/OPG ratio)
m bone formation markers (bALP & OC)
k osteoblast inhibitors (Dkk-1)
In all patients
In all patients
In respondersb
In all patients
Giuliani et al.96a Refractory/relapsed 21 k bone resorption markers (CTX)
m osteoblast numbers
In all patientsc
In responders
Terpos et al.83a
(VMDT regimen)
Refractory/relapsed 62 k bone resorption markers (CTX & TRACP-5b)
k osteoclast stimulators (sRANKL, sRANKL/OPG, MIP-1a)
2 bone formation markers (bALP & OC)
k osteoblast inhibitors (Dkk-1)
In all patients
In all patients
In all patients
In all patients
Abbreviations: bALP, bone alkaline phosphatase; CTX, carboxy-terminal cross-linking telopeptide of type I collagen; Dkk-1, dickkopf-1;
MIP-1a, macrophage inflammatory protein 1a; NTX, amino-terminal cross-linking telopeptide of type I collagen; OC, osteocalcin;
OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-kB ligand; TRACP-5b, tartrate-resistant acid phosphatase isoform type 5b.
aConcomitant bisphosphonates administration in majority of patients.
bbALP was increased only in responders whereas OC was elevated in all patients.
cThis reduction did not reach statistical significance.
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In the current era of concern about bisphosphonate-
associated adverse side-effects (that is, renal impairment,
osteonecrosis of the jaw, subtrochanteric femoral fractures),
bone turnover markers may be of particular use: that is, low
levels of serum ICTP/CTX or urinary NTX may provide impetus
for deciding to lengthen bisphosphonate dosing regimens (that
is, changing from monthly to 3-month intervals). Clinical studies
have started in patients with breast cancer and bone metastases
(BISMARK trial) and are eagerly anticipated in myeloma.
Further, with the development of novel anti-resorptive agents
(denosumab, other anti-RANKL agents) and drugs that enhance
osteoblast function (anti-Dkk-1 antibodies), the measurement of
bone biochemical indices will likely be of particular value.
However, additional trials, such as those described above are
urgently needed (and indeed should be highly encouraged)
before final conclusions are made about the introduction of
biochemical markers of bone remodeling into the routine
clinical care of MM patients.
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